AASLD 2024, 15-19 November, San Diego, CA, USA
 
-------------------------------------
 
Press Release Dec 4 2024 pdf attached
 
Download the PDF here
 
Altea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
 
Primary Endpoint Achieved with 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) after Short Eight Week Treatment Duration
 
Regimen Was Generally Safe and Well-Tolerated
 
Global Phase 3 Program Initiation Expected Early in 2025
 
---------------------------------------